Delcath Systems specializes in proprietary percutaneous hepatic perfusion (PHP) technologies to improve clinical outcomes for patients with rare and life-threatening liver cancers. Its flagship product, the HEPZATO KIT (melphalan for injection/hepatic delivery system), is approved for treating adult patients with metastatic uveal melanoma. In Europe, the company markets the system as a stand-alone medical device under the CHEMOSAT trade name. By isolating the liver's blood flow, the system allows for targeted, high-dose chemotherapy delivery and subsequent filtration of excess drug to reduce side effects. The company operates a single reportable segment focused on the research, development, and commercialization of these hepatic delivery systems.
